Business Wire

MERCY-SHIPS

31.5.2022 07:32:04 CEST | Business Wire | Press release

Share
H.E. President Macky Sall Leads Inauguration of the World’s Largest Purpose-built Hospital Ship, the Global Mercy™

H.E. President of Senegal Macky Sall has inaugurated the world’s largest purpose-built hospital ship and committed to accelerate access to surgical, obstetric and anesthetic care for the nations of Africa. Ceremonies commemorated more than 30 years of service in Africa. International humanitarian organization Mercy Ships and its partners in Africa used the opportunity to come together in an unprecedented and strategic effort to improve access to safer surgery across the continent through a series of milestone events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005472/en/

Representatives from Cameroon, the Union of Comoros, Congo Brazzaville, The Gambia, Guinea-Bissau, and Senegal, gathered on board the Global Mercy to approve a strategic road map to improve surgical care for African nations by 2030, where an estimated 93% of sub-Saharan Africa still lack access to safe surgery.

H.E. President Macky Sall greeted the Heads of State, saying, “We, heads of states present this day, have adopted the Dakar Declaration, which is the result of the meticulous work of our ministers and experts on access to surgical, obstetric and aesthetic care. As President in Office for the African Union, I commit to bring the Dakar Declaration to the summit of heads of state and African governments.”

Gert van de Weerdhof, Mercy Ships Chief Executive Officer said, “At the end of a difficult week for Senegal and for all of us after the tragic events that happened; today, I want to greet you all on this special day here in Dakar, Senegal. The inauguration of the Global Mercy is only one part of the reason we celebrate today. Big decisions have been made here in Dakar.”

President of the Union of the Comoros, Azali Assoumani said, “I pay tribute to Senegal as well as the personnel of Mercy Ships for their commitment to this mission. I applaud this model cooperation contributing to the strengthening of our surgical, obstetric, and anesthetic systems in Africa.”

The Dakar Declaration is an historic agreement following foundational discussions from an International Symposium in Senegal held May 4 – 6, 2022 where experts and ministers of health from 29 African nations met to put forward their commitment to advancing access to surgical, obstetric, and anesthetic care. The result of the Symposium brought a fresh initiative to draft a clear path toward safer and wider access to surgical care in Africa by 2030. Symposium members shared knowledge of their countries’ surgical care situations, addressed gaps and challenges in their national surgical, obstetric and anesthetic plans, and developed new strategies for implementation and capacity building. Prior to the International Symposium, a baseline assessment was carried out with each country and evaluated by a scientific committee.

A first of its kind in Africa, this study has so far collected data about the availability, access, and operation of surgical, obstetric, and anesthetic healthcare systems in 29 of the 47 nations of WHO’s sub-Saharan African region. The survey provides critical insights into Africa’s healthcare systems from the perspective of district hospitals, particularly in the area of surgery. The World Health Organization will leverage the results of the study to complete the ongoing situational analysis of clinical and hospital services, as well as develop and finalize the regional strategy for strengthening clinical and hospital services in Africa.

The comprehensive preliminary report developed by members of the scientific committee led to the drafting of a roadmap to scale up investment in the strengthening of surgical, obstetric, anesthetic, and nursing care in Africa, in line with the Sustainable Development Goals (SDG). A draft Dakar Declaration was prepared and endorsed by the Ministers of Health and approved by visiting African Heads of State.

The new hospital ship, Global Mercy ™ is 174 meters long, 28.6 meters wide and has space for 200 patients, six operating rooms, one laboratory, general outpatient clinics, a dental clinic, and an eye clinic. The hospital decks cover a total area of 7,000 square meters and contain the latest training facilities. When in full service, the ship will be able to accommodate up to 950 people when docked, including crew members and volunteers from all over the world.

A recording of the inauguration ceremony can be found here: https://www.youtube.com/watch?v=HylOGBYaX-0 .

ABOUT MERCY SHIPS:

Global health for the last two decades has focused on individual diseases, while surgical care in low-resource countries has not received the attention it needs. Lack of surgical care resulted in almost 17 million deaths annually.

Mercy Ships is an international faith-based organization that operates hospital ships to deliver free, world-class healthcare services, medical capacity building, and health system strengthening to those with little access to safe surgical care. Since 1978, Mercy Ships has worked in more than 55 countries, with the last three decades focused entirely on partnering with African nations. Each year, volunteer professionals from over 60 countries serve on board the world’s two largest non-governmental hospital ships, the Africa Mercy® and the Global Mercy™. Professionals such as surgeons, dentists, nurses, health trainers, cooks, and engineers dedicate their time and skills to the cause. Mercy Ships has offices in 16 countries and an Africa Bureau. For more information, visit mercyships.org and follow us @MercyShips on social media.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye